# FDA recall D-1876-2019

> **Cardinal Health dba Specialty Pharmaceutical Services** · Class II · drug recall initiated 2019-09-06.

## Product

Nucala (mepolizumab) Injection, 100 mg/mL Prefilled Syringe, Single-Dose, For subcutaneous use only, Rx Only, Manufactured by GlaxoSmithKline LLC, Philadelphia, PA 19112, Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0892-42.

## Reason for recall

Temperature Abuse; Product stored and shipped outside of labeled storage requirements.

## Distribution

Nationwide in the U.S.

## Key facts

- **Recall number:** D-1876-2019
- **Recalling firm:** Cardinal Health dba Specialty Pharmaceutical Services
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2019-09-06
- **Report date:** 2019-10-02
- **Termination date:** 2020-10-08

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** La Vergne, TN, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1876-2019

## Citation

> AI Analytics. FDA recall D-1876-2019. Retrieved 2026-06-25 from https://api.ai-analytics.org/recall/D-1876-2019. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*